Clostridium Difficile Associated Disease Clinical Trial
Official title:
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS 65 TO 85 YEARS OF AGE
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine. The study will assess the lot consistency, safety, and tolerability of the vaccine, and also look at the subjects' immune response to the vaccine.
Serology for B5091008 was delayed due to discussions with the FDA on statistical analysis as well as delays attributed to the COVID pandemic. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01706367 -
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
|
Phase 1 | |
| Active, not recruiting |
NCT02117570 -
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
|
Phase 2 | |
| Completed |
NCT02561195 -
A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
|
Phase 2 | |
| Completed |
NCT02725437 -
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
|
Phase 1 | |
| Completed |
NCT03918629 -
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
|
Phase 3 |